At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
Moxidectin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Potential Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Moxidectin and Placebo for QT Effects in Healthy Volunteers. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This study will investigate the effect of a single oral dose of moxidectin on the QT interval associated with moxidectin plasma concentrations. The effect of moxidectin on other ECG intervals, and on safety, will also be assessed, as will preliminary pharmacokinetics and metabolism
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsQT Effects in Healthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJan 2017
Primary CompletionMar 2017
Study CompletionMay 2017
TodayJul 2026
First PostedJan 6, 2017
Enrollment StartJan 1, 2017
Primary CompletionMar 1, 2017
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.5 years ago
Interventions
Moxidectindrug
Moxidectin is a broad spectrum macrocyclic lactone endectocide
Placeboother